Celonis (CLS.DE): The Hidden Gem in Enterprise Automation with 50% Upside Potential

Celonis SE (CLS.DE) is a German-based software company that pioneered the execution management system (EMS) category, combining process mining, task mining, and AI-powered automation to help enterprises optimize workflows. Unlike traditional RPA or BPM vendors, Celonis provides a data-driven approach to identify inefficiencies and automate processes, making it a core component of the enterprise automation stack.

Investment Thesis: Celonis is uniquely positioned to benefit from the convergence of process mining, AI, and automation. Its platform is increasingly adopted by large enterprises for digital transformation, with a land-and-expand model that drives high net retention rates. The company is on track to achieve $1B+ in ARR by 2026, with improving margins and a strong cash position. Despite its leadership, the stock trades at a discount to high-growth peers due to limited public float and European listing. We expect multiple catalysts to close this gap.

12-Month Catalysts:

  • Q3 2025 earnings: Expect revenue acceleration to 30%+ growth and positive free cash flow for the first time.
  • New product launches: Celonis AI Studio and Process Copilot will drive upsell and cross-sell.
  • Potential IPO or direct listing of Celonis shares on NASDAQ, increasing liquidity and valuation.
  • Strategic partnerships with hyperscalers (AWS, Azure, GCP) expanding distribution.

Key Risks:

  • Competition from SAP Signavio, Microsoft Power Automate, and UiPath.
  • Macro slowdown could delay enterprise software spending.

Valuation: Celonis trades at ~8x forward EV/Sales, a discount to UiPath (10x) and ServiceNow (12x). With 30%+ revenue growth and expanding margins, we see fair value at 12x EV/Sales, implying 50% upside.

Balance Sheet: Celonis has over €500M in cash and no debt, providing ample runway for growth investments and M&A.

Disclaimer: This is not financial advice. Past performance is not indicative of future results. Do your own research before investing.